Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| ADI-001 (allogeneic CAR gamma-delta T cell therapy) | Lupus nephritis (LN), systemic lupus erythematosus (SLE) and SSc | Phase 1 | Sep 30, 2026 | — |
| ADI-001 | Rheumatoid Arthritis (RA) | Phase 1 | Dec 31, 2026 | — |
Upcoming milestones
Company profile
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Lupus nephritis (LN), systemic lupus erythematosus (SLE) and SSc
Rheumatoid Arthritis (RA)
Data readout